Skip to main content

Table 2 Variables measured by the continuous glucose monitoring system and plaque characteristics detected by optical coherence tomography

From: The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE—A multicenter randomized controlled trial

Variables Change in the vildagliptin group (6 months—baseline) Change in the control group (6 months—baseline) Difference between mean change
Difference 95% confidence interval p Value
Variables measured by the continuous glucose monitoring system
  (n = 10) (n = 10)    
MAGE, mg/dl − 20.2 ± 18.0 2.6 ± 12.7 − 18.8 − 30.8 to − 6.8 0.0064
Time in hyperglycemia, hours − 7.9 ± 14.1 − 0.8 ± 10.2 − 3.7 − 11.4 to 3.9 0.350
Time in hypoglycemia, hours − 0.8 ± 3.5 4.7 ± 15.4 − 6.1 − 15.3 to 3.1 0.209
Mean BS, mg/dl − 3.3 ± 17.3 0.4 ± 13.3 0.3 − 9.5 to 10.0 0.960
Maximum BS, mg/dl − 36.3 ± 65.8 1.2 ± 37.6 − 11.5 − 43.1 to 20.0 0.482
Minimum BS, mg/dl 5.5 ± 24.8 7.6 ± 23.1 4.8 − 10.3 to 20.0 0.538
HOMA R 0.6 ± 0.7 0.1 ± 1.0 0.5 − 0.3 to 1.3 0.243
Plaque characteristics detected by optical coherence tomography
  (n = 22) (n = 25)    
MLA, mm2 0.62 ± 1.94 − 0.29 ± 0.65 0.99 − 0.26 to 2.23 0.120
Lipid length, mm − 0.10 ± 1.40 − 0.52 ± 2.37 0.03 − 1.28 to 1.34 0.963
Lipid arc, ° − 9.00 ± 25.57 15.87 ± 16.82 − 22.82 − 40.56 to − 5.09 0.017
Minimum FCT, μm 35.75 ± 50.80 − 15.19 ± 25.02 42.73 15.34 to 70.12 0.0022
  1. Mean ± standard deviation (n) for continuous variables
  2. Time in hyperglycemia was defined as the time when blood glucose levels were above 140 mg/dl. Time in hypoglycemia was defined as the time when blood glucose levels were under 70 mg/dl
  3. BS = blood sugar; FCT = fibrous cap thickness; HOMA R = homeostasis model assessment ratio; MAGE = mean amplitude of glycemic excursion; MLA = minimum lumen area